TY - JOUR
T1 - Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex
AU - Cohn, Ronald D.
AU - Durbeej, Madeleine
AU - Moore, Steven A.
AU - Coral-Vazquez, Ramón
AU - Prouty, Sally
AU - Campbell, Kevin P.
PY - 2001
Y1 - 2001
N2 - Cardiomyopathy is a multifactorial disease, and the dystrophin-glycoprotein complex has been implicated in the pathogenesis of both hereditary and acquired forms of the disease. Using mouse models of cardiomyopathy made by ablating genes for components of the sarcoglycan complex, we show that long-term treatment with verapamil, a calcium channel blocker with vasodilator properties, can alleviate the severe cardiomyopathic phenotype, restoring normal serum levels for cardiac troponin I and normal cardiac muscle morphology. Interruption of verapamil treatment leads again to vascular dysfunction and acute myocardial necrosis, indicating that predilection for cardiomyopathy is a continuing process. In contrast, verapamil did not prevent cardiac muscle pathology in dystrophin-deficient mdx mice, which neither show a disruption of the sarcoglycan complex in vascular smooth muscle nor vascular dysfunction. Hence, our data strongly suggest that pharmacological intervention with verapamil merits investigation as a potential therapeutic option not only for patients with sarcoglycan mutations, but also for patients with idiopathic cardiomyopathy associated with myocardial ischemia not related to atherosclerotic coronary artery disease.
AB - Cardiomyopathy is a multifactorial disease, and the dystrophin-glycoprotein complex has been implicated in the pathogenesis of both hereditary and acquired forms of the disease. Using mouse models of cardiomyopathy made by ablating genes for components of the sarcoglycan complex, we show that long-term treatment with verapamil, a calcium channel blocker with vasodilator properties, can alleviate the severe cardiomyopathic phenotype, restoring normal serum levels for cardiac troponin I and normal cardiac muscle morphology. Interruption of verapamil treatment leads again to vascular dysfunction and acute myocardial necrosis, indicating that predilection for cardiomyopathy is a continuing process. In contrast, verapamil did not prevent cardiac muscle pathology in dystrophin-deficient mdx mice, which neither show a disruption of the sarcoglycan complex in vascular smooth muscle nor vascular dysfunction. Hence, our data strongly suggest that pharmacological intervention with verapamil merits investigation as a potential therapeutic option not only for patients with sarcoglycan mutations, but also for patients with idiopathic cardiomyopathy associated with myocardial ischemia not related to atherosclerotic coronary artery disease.
UR - http://www.scopus.com/inward/record.url?scp=0035139829&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035139829&partnerID=8YFLogxK
U2 - 10.1172/JCI11642
DO - 10.1172/JCI11642
M3 - Article
C2 - 11160141
AN - SCOPUS:0035139829
SN - 0021-9738
VL - 107
SP - R1-R7
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 2
ER -